UCLA Vine Street Clinic

Purpose 2: A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Non-binary People ≥ 16 Years of Age who Have Sex with Male Partners and are at Risk for HIV Infection
Inflammation in Methamphetamine and STIs (aka IMSTI)
Expression of stress markers in MSM living with HIV receiving contingency management for methamphetamine use disorder (a.k.a. “EXPRESS+”)
HVTN 302: A phase 1, randomized, open-label clinical trial to evaluate the safety and immunogenicity of HIV trimer mRNA vaccines in healthy, HIV-uninfected adult participants.
Phase I Safety-Interaction Study of Mirtazapine for the Treatment of Methamphetamine Use Disorder
Moderna’s mRNA-1273 vaccine, The COVE Study

About

CBAM is a multidisciplinary center that seeks to advance the prevention and treatment of chronic illnesses, especially in communities with health disparities. As part of the UCLA Department of Family Medicine, CBAM works at the intersection of academia and community with a focus on treating addictions and preventing the spread of HIV.

© The UCLA Center for Behavioral & Addiction Medicine (CBAM). All Rights Reserved.